Diabetes Obesity & Metabolism

Article	Citations
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside	416
Disparity in the rural‐urban distribution of clinical trial sites used in studies cited by diabetes treatment guidelines	208
	138
Association between stress hyperglycaemia and in‐hospital cardiac events after coronary artery bypass grafting in patients without diabetes: A retrospective observational study of 5450 patients	117
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study	112
	112
Diabetes, Obesity and Metabolism	93
	89
Body mass index and remote ischaemic conditioning efficacy in acute ischaemic stroke patients: A post hoc analysis of the Remote Ischaemic Conditioning for Acute Moderate Ischaemic Stroke (RICAMIS) tr	86
A meta‐analysis of the association between RBP4 rs3758539 genotype and metabolic syndrome factors	86
Obesity‐associated metabolites in relation to type 2 diabetes risk: A prospective nested case‐control study of the CARRS cohort	78
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial	75
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump	71
Assessment of circulating insulin using liquid chromatography‐mass spectrometry during insulin glargine treatment in type 2 diabetes: Implications for estimating insulin sensitivity and β‐cell functio	69
Surfing the waves of the COVID‐19 pandemic with diabetes mellitus: Analysis of changes in the diabetes therapy, metabolism and physical activity of 92 992 people living with type 1 or type	67
Reduction of clinically important low glucose excursions with a long‐term implantable continuous glucose monitoring system in adults with type 1 diabetes prone to hypoglycaemia: the France Adoption Ra	66
Mediators of the effects of canagliflozin on N‐terminal pro‐brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial	66
Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists	65
Interactions between age, sex and visceral adipose tissue on brain ageing	64
Regional socioeconomic deprivation associated with the use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in adults with type 2 diabetes in Germany	63
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	62
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial	62
Associations of body mass index, waist circumference and the weight‐adjusted waist index with daily living ability impairment in older Chinese people: A cross‐sectional study of the Chinese Longitudin	62
Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada	61
Types of diabetes during pregnancy and risk of depression and anxiety in offspring from childhood to young adulthood	61

Short‐term efficacy and safety of metformin in individuals with type 2 diabetes and mild hepatic impairment: A propensity score‐matched real‐world study	59
High‐protein vegan and omnivorous diets improve peripheral insulin sensitivity to a similar extent in people with type 2 diabetes	58
The predictive value of estimated glucose disposal rate and its association with myocardial infarction, heart failure, atrial fibrillation and ischemic stroke	57
Sustained weight reduction following 12 weeks of intermittent fasting intervention in people with insulin‐treated type 2 diabetes—Two‐year follow‐up of the randomised controlled InterFast‐2	56
Correction to “Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP	53
Diabetes, Obesity and Metabolism	51
Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice	51
Glucagon‐like peptide‐1 analogues reduce alcohol intake	51
Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point‐of‐care glucose testing in a non‐intensive care unit setting: A heterogeneity of treatment	48
Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study	47
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (	47
Glucose control using fast‐acting insulin aspart in a real‐world setting: A 1‐year, two‐centre study in people with type 1 diabetes using continuous glucose monitoring	46
Issue Information	45
Glycaemic control and sepsis risk in adults with type 1 diabetes	42
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries	42
Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population	42
	41
Back Cover	41
	40
Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID‐19 patients with diabetes: A population‐based study in Lombardy	40
Adiposity indicators exhibit depot‐ and sex‐specific associations with multimorbidity onset: A cohort study of the UK Biobank	40
Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology	40
Patterns of initial and first‐intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010–2020: A retrospective population‐based cohort study	40
Issue Information	39
An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management	39
Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time	39
	38
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 s	38
Clinical evaluation of a decision support system for glucose infusion in hypoglycaemic clamp experiments	37
	37
Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study	37
Acute concomitant glucose‐dependent insulinotropic polypeptide receptor antagonism during glucagon‐like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake i	36
Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes	34
The impact of postbariatric hypoglycaemia on driving performance: A randomized, single‐blind, two‐period, crossover study in a driving simulator	34
Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes	33
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial	33
	33
	33
	32
Biologically plausible trends suggesting that a low‐protein diet may enhance the effect of flozination caused by the sodium‐glucose cotransporter‐2 inhibitor dapagliflozin on albuminuria	32
Diabetes, Obesity and Metabolism	32
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial	32
A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, obser	32
Glucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients	31
	31
Parent and patient knowledge of nasal glucagon use and efficacy in a large cohort of Italian children and adolescents with type 1 diabetes	31
Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: AVERTIS CVsubstudy	31
Issue Information	31
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk	30
Issue Information	30

The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first sig	29
Glucose‐lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types	29
Longevity of the novel ConvaTec infusion set with Lantern technology	29
Issue Information	28
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease	28
Patient‐reported outcomes in adults with type 1 diabetes in global real‐world clinical practice: The SAGE study	28
Inside Front Cover	28
FOXO1 reduces STAT3 activation and causes impaired mitochondrial quality control in diabetic cardiomyopathy	28
Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects	28
Nutritional strategies for correcting low glucose values in patients with postbariatric hypoglycaemia: A randomized controlled three‐arm crossover trial	28
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐	28
REduced‐Carbohydrate intervention for managing Obesity and Reduction of gestational Diabetes (RECORD): A randomized controlled feasibility trial	28
Diabetes, Obesity and Metabolism	27
	27
Diabetes, Obesity and Metabolism	27
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients	27
	27
Back Cover	27
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis	26
Metabolically healthy obesity and left ventricular geometric remodelling in Chinese children	26
Clinical evidence for high‐risk CE‐marked medical devices for glucose management: A systematic review and meta‐analysis	26
ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes	26
Bariatric surgery and all‐cause mortality: A methodological review of studies using a non‐surgical comparator	25
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	25
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	25
Adapting study designs of Mendelian randomization for disease complications: Insights from type 1 diabetes complications research	25
Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus	25
Elucidating the glucose‐lowering effect of the bile acid sequestrant sevelamer	24
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment	24
Persistence with insulin pump therapy among children and young adults with type 1 diabetes in Germany: An update	24
Effect of multifactorial intensive treatment in patients with diabetic kidney disease: A meta‐analysis with trial sequential analysis	24
Efficacy and safety of a basal insulin + 2‐3 oral antihyperglycaemic drugs regimen versus a twice‐daily premixed insulin + metformin regimen after short‐term intensive insulin therapy in individuals w	24
A novel structured, volume‐based, weight‐loss and health programme combined with respiratory muscle training helps reduce weight and cardiovascular risk in people with obesity	24
Glucose‐dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double‐blind, placebo‐controlled,	23
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease	23
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR stud	23
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	23
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes	23
GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	23
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, cross	23
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic	23
Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic	23
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial	22
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliM	22
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	22
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin	22
Inclusion of drugs on the World Health Organization's Essential Medicines List: A game‐changer for obesity?	22
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis	21
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	21
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups	21
Pharmacodynamics and pharmacokinetics of extended‐release metformin in patients with type 2 diabetes and chronic kidney disease stage 3B	21
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long‐acting glucagon analogue HM15136 in overweight and obese patients with co‐morbiditi	21
Effects of somatostatin receptor type 2 antagonism during insulin‐induced hypoglycaemia in male rats with prediabetes	21
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	21
Repeated detection of non‐alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults	21
A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with m	20
The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD‐REIN cohort study	20
	20
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial	20
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials	20
Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial	20
Insights into the impact of sodium‐glucose cotransporter 2 inhibition on urinary tract malignancy: A two‐sample Mendelian randomization	20
The significance of coefficient of variation as a measure of hypoglycaemia risk and glycaemic control in real world users of the automated insulin delivery MiniMed 780G system	20
Time in tight range in automated insulin delivery system users: Real‐world data from children and adolescents with type 1 diabetes	20
Postprandial glucose‐management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence	20
Evaluating different low‐density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation stu	19
Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide (SHR20004), a novel GLP‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus	19
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	19
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	19
Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies	19
The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes‐related and cancer outcomes	19
Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study	19
Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance	19
Sex‐ and time‐specific associations of obesity with glycaemic traits: A two‐step multivariate Mendelian randomization study	19
Trajectory of haemoglobin A1c and incidence of cardiovascular disease in patients with type 2 diabetes mellitus	19
A biweekly DPP‐4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group	19
The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review	19
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, plac	19
Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes	18
Risk of diabetic macular oedema with sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes patients: A multi‐institutional cohort study in Taiwan	18

A real‐world study of user characteristics, safety and efficacy of open‐source closed‐loop systems and Medtronic 670G	18
Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐SWITCH study	18
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis	18
Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes	18
Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes	18
	18
Clinical features of type 1 diabetes in older adults and the impact of intermittently scanned continuous glucose monitoring: An Association of British Clinical Diabetologists (ABCD) study	18
Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes	18
Human placenta‐derived mesenchymal stem cells ameliorate diabetic kidney disease by modulating the T helper 17 cell/ regulatory T‐cell balance through the programmed death 1 / programmed de	18
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	17
Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G	17
Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials	17
Reducing hyperglucagonaemia in type 2 diabetes using low‐dose glibenclamide: Results of the LEGEND‐A pilot study	17
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	17
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double‐blinded, placebo‐controlled trial	17
Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme	17
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis	17
Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A mod	17
Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post‐hoc machine learning analysis of ACCORD trial data	17
Effect of sodium‐glucose cotransporter‐2 inhibitors on myocardial infarction incidence: A systematic review and meta‐analysis of randomized controlled trials and cohort studies	17
Efficacy of adipose‐derived mesenchymal stem cell therapy in the treatment of chronic micro‐ and macrovascular complications of diabetes	17
Impact of the COVID‐19 pandemic on new diagnoses of type 2 diabetes in England	17
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled tri	17
The effects of antihypertensive drugs on glucose metabolism	16
Joint longitudinal and time‐to‐event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL	16
Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observational real‐world cohort study	16
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized con	16
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023	16
Increased prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes and hypertension: The SWEET international database	16
Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery	16
Fracture risk revisited: Bone mineral density T‐score and fracture risk in type 2 diabetes	16
Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease	16
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III	16
Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized,	16
Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow‐up (DPV) database	16
Sex‐specific associations between haemoglobin glycation index and the risk of cardiovascular and all‐cause mortality in individuals with pre‐diabetes and diabetes: A large prospective cohort study	16
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study	16
Diabetes, Obesity and Metabolism	16
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance	16
Nonalcoholic fatty liver disease from a primary care perspective	16
Effectiveness of low‐carbohydrate diets for long‐term weight loss in obese individuals: A meta‐analysis of randomized controlled trials	16
Separate and combined effect of visit‐to‐visit glycaemic variability and mean fasting blood glucose level on all‐cause mortality in patients with type 2 diabetes: A population‐based cohort study	16
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	16
Analyses of potential causal contributors to increased waist/hip ratio‐associated cardiometabolic disease: A combined and sex‐stratified Mendelian randomization study	16
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial	16
Are novel glucose‐lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta‐trial sequential analysis to address disparities in cardiovascular and renal outco	15
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS‐1 monotherapy trial	15
Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study	15
Pathophysiological interactions between sarcopenia and type 2 diabetes: A two‐way street influencing diagnosis and therapeutic options	15
A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?	15
Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study	15
The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control	15
Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis	15
Real‐world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed‐loop use	15
Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes	15
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy	15
Exploring causal effects of gut microbiota and metabolites on body fat percentage using two‐sample Mendelian randomization	15
Response to the letter from Horowitz et al. to the Editor relating to the publication ‘Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects wit	15
5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine	15
The benefit of dexamethasone in patients with COVID‐19 infection is preserved in patients with diabetes	15
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa	15
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction	15
Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study	14
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross‐sectional survey	14
Diabetes, Obesity and Metabolism	14
Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes	14
Tirzepatide, a dual receptor agonist of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1, enhances β‐cell survival and maintenance markers in obese diabetic ovariectomized mice	14
Effects of dipeptidyl peptidase‐4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents	14
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes	14
Non‐invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta‐analysis	14
Global and regional estimates of hip fracture burden associated with type 1 diabetes from 1990 to 2021	14
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	14
Effects of sodium‐glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients	14
A novel, centrally acting mammalian aminosterol, ENT‐03, induces weight loss in obese and lean rodents	14
iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan‐L‐CN study	14
Relationship between weight‐adjusted‐waist index and all‐cause and cardiovascular mortality in individuals with type 2 diabetes	14
The high hourly overnight variability of insulin requirements as an explanation for the superiority of automated insulin delivery systems	13
Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme	13
Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensifi	13
The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis	13
Key biomarkers in type 2 diabetes patients: A systematic review	13
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	13
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion	13
A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesi	13
Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability	13
	13
iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc	13
Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes	13
Association between two novel anthropometric measures and type 2 diabetes in a Chinese population	13
Earlier detection of gestational diabetes impacts on medication requirements, neonatal and maternal outcomes	13
Prevalence of individuals with diabetes and chronic kidney disease indicated for finerenone treatment in the United States: A National Health and Nutrition Examination Survey‐based estimation	13
Association of hypertension and long‐term blood pressure changes with new‐onset diabetes in the elderly: A 10‐year cohort study	13
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020	12
Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY stu	12
An update and overview of the various health‐related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and typ	12